Tissue-resident macrophages (Mϕs) play a key role in innate immune surveillance against tissue-invading pathogens. In addition, they have been characterized as anti-inflammatory Mϕs responsible for maintaining tissue homeostasis and resolving inflammatory responses ([@r1]). For example, intestinal resident CX~3~CR1^high^ Mϕs derived from Ly6C^high^ CCR2^+^ monocytes after birth ([@r2], [@r3]) mediate innate immune defense against intestinal microorganisms by exerting high phagocytic activity ([@r4]). To maintain mucosal tolerance, noninflammatory gene expression patterns in intestinal CX~3~CR1^high^ Mϕs are precisely controlled through IL-10 receptor signaling-dependent mechanisms ([@r5], [@r6]). Intestinal CX~3~CR1^high^ Mϕs in *Il10ra*-deficient mice displayed the elevated expression of Toll-like receptor (TLR)-dependent proinflammatory mediators such as *Il12b*, *Il23a*, and *Nos2*, while a subset of TLR-inducible genes such as *Il6* and *Tnf* was unchanged ([@r5]). Accordingly, large intestinal CX~3~CR1^high^ Mϕs from *Il10*^*−/−*^ mice did not show increased IL-6 production ([@r7]). Thus, the activity of intestinal CX~3~CR1^high^ Mϕs might be modulated by an unknown IL-10--independent mechanism.

In addition to precursor heterogeneity, local environmental factors are implicated in the diversity of tissue-resident Mϕs by inducing tissue-specific transcription factors as well as epigenetic modifications, leading to unique transcriptional profiles ([@r8], [@r9]). When hemorrhage occurs in damaged tissues, hemoglobin provides either an anti-inflammatory feature or a restorative function for infiltrating Mϕs through a scavenger receptor such as CD163 ([@r10][@r11][@r12][@r13][@r14]--[@r15]). Among the colonoscopic features, bleeding within the mucosa is commonly seen in patients with ulcerative colitis that is a form of inflammatory bowel disease ([@r16]). However, whether heme evokes the noninflammatory profiles in Mϕs, thereby contributing to mucosal healing, is unclear.

Spi-C, which belongs to the Spi subfamily of Ets transcription factors including PU.1, Spi-B, and Spi-D ([@r17]), was reported to regulate the differentiation of splenic red pulp Mϕs (RPMϕs) and F4/80^+^ VCAM^+^ bone marrow Mϕs (BMMϕs) ([@r18], [@r19]) and the development of B lymphocytes ([@r20][@r21]--[@r22]). In addition, erythrocyte-derived heme is a tissue factor that drives the expression of *Spic* during the development of RPMϕs and F4/80^+^ VCAM^+^ BMMϕs ([@r19]). However, the function of Spi-C in the regulation of innate immune responses remains poorly understood.

In this study, we identified the mechanism by which heme-mediated Spi-C negatively regulates a subset of TLR-inducible genes in intestinal Mϕs through disruption of IRF5-NF-κB p65 complex formation to provide noninflammatory profiles for intestinal Mϕs, thereby maintaining intestinal homeostasis.

Results {#s1}
=======

Expression of Spi-C in Intestinal CX~3~CR1^high^ Mϕs. {#s2}
-----------------------------------------------------

Unlike other tissue-resident Mϕs, transcription factors that regulate the differentiation and function of CX~3~CR1^high^ Mϕs in the large intestine are poorly understood. Thus, to identify transcription factors specifically expressed in CX~3~CR1^high^ Mϕs among large intestinal innate myeloid cells, we comprehensively analyzed gene expression profiles in CX~3~CR1^high^ Mϕs, CX~3~CR1^−^ CD11b^+^ CD11c^+^ cells, CD11b^−^ CD11c^high^ DCs, and CD11b^+^ CD11c^−^ cells ([*SI Appendix*, Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). Among four subsets, CX~3~CR1^high^ Mϕs highly expressed *Spic*. *Spic*^*igfp/igfp*^ mice showed that a subpopulation of CD11b^+^ innate myeloid cells in the colon, small intestine, and mesenteric lymph nodes (MLN) expressed Spi-C, as did those in the spleen and bone marrow ([@r19]) ([Fig. 1*A*](#fig01){ref-type="fig"}). In the colon, Spi-C--expressing CD11b^+^ CD11c^+/−^ cells highly expressed CX~3~CR1 in both a steady state and a dextran sodium sulfate (DSS)-induced inflammatory state ([*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)), suggesting that Spi-C is selectively expressed in CX~3~CR1^high^ Mϕs among large intestinal innate myeloid cells.

![*Lyz2-cre*; *Spic*^*flox/flox*^ mice showed exacerbated intestinal inflammation following DSS administration. (*A*) Flow cytometric plots of Spi-C-EGFP-- and CD11b-expressing cells. The cells from the spleen, bone marrow (BM), large intestine (LI), small intestine (SI), mesenteric lymph nodes (MLN), liver, and peritoneal cavity (PEC) from wild-type and *Spic*^IRES-GFP/GFP^ mice were stained with anti-CD45 antibody, anti-CD11b antibody, and 7-AAD. All data are representative of two independent experiments. (*B*−*F*) *Spic*^*flox/flox*^ and *Lyz2-cre*; *Spic*^*flox/flox*^ mice were administered with 1.5% DSS for 7 d. (*B*) Weight changes of *Spic*^*flox/flox*^ (*n* = 9) and *Lyz2-cre*; *Spic*^*flox/flox*^ (*n* = 8) mice. \**P* \< 0.05. (*C* and *D*) Bleeding score (*C*) and stool score (*D*) of mice administered with 1.5% DSS for 10 d (*n* = 5 per group). \**P* \< 0.05, \*\*\*\**P* \< 0.001. Mean ± SEM from two independent experiments are shown. (*E*) H&E staining and histopathological score of *Spic*^*flox/flox*^ (*n* = 9) and *Lyz2-cre*; *Spic*^*flox/flox*^ (*n* = 8) mice. \**P* \< 0.05. (*F*) The frequency (*Upper*) and number (*Bottom*) of IFN-γ--, IL-17--, and IL-10--producing CD4^+^ T cells from *Spic*^*flox/flox*^ (*n* = 7) and *Lyz2-cre*; *Spic*^*flox/flox*^ (*n* = 4) mice. \**P* \< 0.05. All graphs show mean ± SEM from two independent experiments.](pnas.1808426115fig01){#fig01}

Exacerbated Colitis in Myeloid Lineage Cell-Specific Spi-C--Deficient Mice. {#s3}
---------------------------------------------------------------------------

To assess the physiological role of Spi-C in intestinal CX~3~CR1^high^ Mϕs, myeloid lineage cell-specific Spi-C--deficient (*Lyz2-cre*; *Spic*^*flox/flox*^) mice were generated ([*SI Appendix*, Fig. S2 *A*--*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). The expression of *Spic* mRNA was markedly reduced in large intestinal CX~3~CR1^high^ Mϕs in *Lyz2-cre*; *Spic*^*flox/flox*^ mice compared with *Spic*^*flox/flox*^ mice ([*SI Appendix*, Fig. S2*D*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). However, the frequency of CX~3~CR1^high^ Mϕs was not altered in the large intestinal lamina propria ([*SI Appendix*, Fig. S2*E*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In the steady state, there was no difference in IL-17--, IFN-γ--, and IL-10--producing CD4^+^ T cells as well as in Foxp3^+^ Treg cells in the colon, MLN, and spleen between *Spic*^*flox/flox*^ and *Lyz2-cre*; *Spic*^*flox/flox*^ mice ([*SI Appendix*, Fig. S2 *F* and *G*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In the spleen of *Lyz2-cre*; *Spic*^*flox/flox*^ mice, the number of RPMϕs was normal ([*SI Appendix*, Fig. S3*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In addition, *Spic* expression was not reduced in RPMϕs isolated from *Lyz2-cre*; *Spic*^*flox/flox*^ mice ([*SI Appendix*, Fig. S3*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). This might be due to the lower expression level of *Lyz2* in RPMϕs than intestinal in CX~3~CR1^high^ Mϕs ([*SI Appendix*, Fig. S3*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)).

We investigated whether Spi-C in CX~3~CR1^high^ Mϕs regulates intestinal inflammation by orally administering 1.5% DSS. Compared with *Spic*^*flox/flox*^ mice, *Lyz2-cre*; *Spic*^*flox/flox*^ mice showed greater weight loss, more profound bleeding in the stools, slightly increased pasty stools, and more severe intestinal pathologies ([Fig. 1 *B*--*E*](#fig01){ref-type="fig"}). In addition, the number of IL-17--producing CD4^+^ T cells was increased in the colon, but not in the MLN and spleen of *Lyz2-cre*; *Spic*^*flox/flox*^ mice following DSS administration compared with *Spic*^*flox/flox*^ mice ([Fig. 1*F*](#fig01){ref-type="fig"}). These findings indicate that Spi-C in intestinal CX~3~CR1^high^ Mϕs plays an important role in the suppression of intestinal inflammation.

Attenuation of DSS-Induced Colitis by Heme Is Spi-C--Dependent. {#s4}
---------------------------------------------------------------

A previous study identified heme as an inducer of *Spic* expression in Mϕs ([@r19]). Heme-associated iron was present in the intestinal lamina propria as well as the spleen in both a steady state and a DSS-induced inflammatory condition ([*SI Appendix*, Fig. S4*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In addition, hemoglobin and iron were detected in the intestinal lumen in the steady state, and their concentrations were increased after DSS administration ([*SI Appendix*, Fig. S4*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)), thus indicating that intestinal Mϕs have a chance to be exposed to heme in the intestine. Therefore, we examined whether the induction of *Spic* expression in CX~3~CR1^high^ Mϕs by heme mediates the suppression of intestinal inflammation. The i.p. injection of hemin (a Fe^3+^ oxidization product of heme) up-regulated *Spic* expression as well as iron/heme metabolism-related genes such as *Hmox1*, *Slc40a1*, and *Blvrb* in large intestinal CD11b^+^ CD11c^+^ cells ([*SI Appendix*, Fig. S4*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). Among CD11b^+^ innate myeloid cells in the large intestinal lamina propria of hemin-injected mice, CX~3~CR1^high^ Mϕs most highly expressed *Spic* ([*SI Appendix*, Fig. S4*D*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). We next examined the therapeutic effect of heme on DSS-induced colitis in *Spic*^*flox/flox*^ and *Lyz2-cre*; *Spic*^*flox/flox*^ mice ([Fig. 2](#fig02){ref-type="fig"}). Without hemin pretreatment, *Lyz2-cre*; *Spic*^*flox/flox*^ mice exhibited severe clinical parameters such as weight loss, stool bleeding, stool consistency, and colon shortening ([Fig. 2 *A*--*D*](#fig02){ref-type="fig"}), which was associated with worsened colonic histopathology ([Fig. 2*E*](#fig02){ref-type="fig"}), compared with those in *Spic*^*flox/flox*^ mice. In *Spic*^*flox/flox*^ mice, hemin treatment reduced all of the clinical parameters with a marked amelioration of intestinal pathology, as reported previously ([@r23]). In contrast, *Lyz2-cre*; *Spic*^*flox/flox*^ mice suffered from profound weight loss with severe stool bleeding and shortening of the colon even after hemin treatment, although a partial suppression of the weight loss and amelioration of stool consistency were observed. Moreover, histological analysis did not show a hemin-mediated remediation of pathological changes in *Lyz2-cre*; *Spic*^*flox/flox*^ mice. In accordance with the reduced severity of colitis in the colons of *Spic*^*flox/flox*^ mice, but not of *Lyz2-cre*; *Spic*^*flox/flox*^ mice, the number of colitogenic Th1 and Th17 cells after DSS administration was markedly decreased by hemin pretreatment ([Fig. 2*F*](#fig02){ref-type="fig"}). Without pretreatment with hemin, production of IL-6 and IL-17 in the colon was slightly increased in *Lyz2-cre*; *Spic*^*flox/flox*^ mice compared with that in *Spic*^*flox/flox*^ mice ([*SI Appendix*, Fig. S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In *Spic*^*flox/flox*^ mice pretreated with hemin, production of proinflammatory cytokines including IL-6, IL-17, IFN-γ, and IL-1α in the colon was greatly reduced compared with that in untreated *Spic*^*flox/flox*^ mice. In contrast, *Lyz2-cre*; *Spic*^*flox/flox*^ mice did not show the hemin-mediated suppression of IL-17, IFN-γ, and IL-1α production in the colons, although a modest reduction of IL-6 production was induced. These findings suggest that Spi-C is required for the heme-dependent suppression of intestinal inflammation.

![Minimal therapeutic effects of hemin on symptoms of DSS-induced colitis in *Lyz2-cre*; *Spic*^*flox/flox*^ mice. *Spic*^*flox/flox*^ and *Lyz2-cre*; *Spic*^*flox/flox*^ mice intraperitoneally injected with 1 mg hemin or vehicle on days −2 and −1 of DSS administration and administered with 1.5% DSS for 7 d (*n* = 8--9 per group) (*A*, *E*, and *F*) or 11 d (*n* = 5--8 per group) (*B*--*D*). (*A*) Weight changes. \**P* \< 0.05, \*\*\*\**P* \< 0.001, ^\#^*P* \< 0.05, ^\$^*P* \< 0.05, ^\$\$^*P* \< 0.01, ^&^*P* \< 0.05, ^&&^*P* \< 2 × 10^−5^. (*B* and *C*) Bleeding score (*B*) and stool score (*C*). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.005, ^\#^*P* \< 0.05, ^\$^*P* \< 0.05, ^&^*P* \< 0.05, \**P* denotes significance between heme-treated control and *Spic* mutant mice, ^\#^*P* denotes significance between vehicle-injected control and *Spic* mutant mice, ^\$^*P* denotes significance between vehicle-injected and heme-injected *Spic* mutant mice, and ^&^*P* denotes significance between vehicle-injected and heme-injected control mice (*A*--*C*). (*D*) Colon length. \*\*\**P* \< 0.005, \*\*\*\**P* \< 0.001. (*E*) Representative colon sections (*Upper*) and histological score (*Bottom*) of the colons. \**P* \< 0.05, \*\*\**P* \< 0.005. (*F*) Frequency (*Left*) and number (*Right*) of IFN-γ--, IL-17--, and IL-10--producing CD4^+^ T cells. \**P* \< 0.05, \*\**P* \< 0.01.](pnas.1808426115fig02){#fig02}

Decreased Expression of a Subset of TLR-Dependent Genes by Heme-Inducible Spi-C. {#s5}
--------------------------------------------------------------------------------

To determine how Spi-C controls the function of intestinal CX~3~CR1^high^ Mϕs, we investigated the overall gene expression patterns in BMDMϕs prepared from *Spic*^*flox/flox*^ and *Lyz2-cre*; *Spic*^*flox/flox*^ mice. BMDMϕs were stimulated with or without LPS following hemin treatment and used for RNA-seq analysis. In *Spic*^*−/−*^ BMDMϕs stimulated with LPS, 85 genes were up-regulated compared with LPS-stimulated *Spic*^*flox/flox*^ BMDMϕs ([*SI Appendix*, Table S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). We focused on proinflammatory cytokine genes such as *Il6* and *Il1a* among these genes because they were reported to promote intestinal inflammation ([@r24][@r25][@r26][@r27]--[@r28]). To confirm the RNA-seq results, we analyzed the LPS-induced expression of *Il6*, *Il1a*, and *Tnf* in hemin-pretreated Mϕs derived from peripheral blood monocytes (PB-MO) isolated from *Spic*^*flox/flox*^ and *Lyz2-cre*; *Spic*^*flox/flox*^ mice using quantitative RT-PCR ([Fig. 3*A*](#fig03){ref-type="fig"}). The expression of *Il6* and *Il1a*, but not *Tnf*, was markedly increased in *Spic*^*−/−*^ PB-MOMϕs compared with control cells ([Fig. 3*A*](#fig03){ref-type="fig"}). To confirm the effects of Spi-C on LPS-inducible gene expression, we generated RAW264.7 cells stably expressing Spi-C ([Fig. 3 *B* and *C*](#fig03){ref-type="fig"}) and analyzed the expression of *Il6*, *Il1a*, and *Tnf* ([Fig. 3*D*](#fig03){ref-type="fig"}). Spi-C--expressing RAW264.7 cells showed a marked decrease in the expression of *Il6* and *Il1a*, but not of *Tnf*, following LPS stimulation. In accordance with the mRNA expression patterns, the production of IL-6 and IL-1α, but not of TNF-α, by hemin-treated *Spic*^*−/−*^ PB-MOMϕs in response to LPS was augmented compared with control cells ([Fig. 3*E*](#fig03){ref-type="fig"}). These findings indicate that the heme-mediated expression of Spi-C negatively regulates the expression of a subset of LPS-inducible genes.

![Expression of a subset of LPS-inducible genes up-regulated in *Spic*^*−/−*^ Mϕs. (*A*) PB-MOMϕs prepared from control and *Spic* mutant mice were stimulated with LPS following pretreatment with hemin for 18 h and analyzed for the expression of *Il6*, *Il1a*, and *Tnf*. Graphs show the mean ± SEM of three independent experiments. \**P* \< 0.05. (*B*) Expression of *Spic* in RAW264.7 cells stably expressing Spi-C-His and control cells. Graphs show the mean ± SD. Data are representative of four independent experiments. \**P* \< 0.05. (*C*) Western blot analysis with anti-His and anti--β-actin antibodies using Spi-C-His stably expressing RAW264.7 cells and control cells. Data are representative of two independent experiments. (*D*) RAW264.7 cells stably expressing Spi-C-His and control cells stimulated with LPS were analyzed for the expression of *Il6*, *Il1a*, and *Tnf*. Graphs show the mean ± SD. Data are representative of two independent experiments. \**P* \< 0.05, \*\*\**P* \< 0.005. n.s., not significant. (*E*) Production of IL-6, IL-1α, and TNF-α in response to LPS by hemin-pretreated PB-MOMϕs. Graphs show the mean ± SEM from four independent experiments. \**P* \< 0.05. n.d., not detected; n.s., not significant.](pnas.1808426115fig03){#fig03}

Enhanced Production of IL-6 and IL-1α by *Spic*^*−/−*^ Intestinal CX~3~CR1^high^ Mϕs. {#s6}
-------------------------------------------------------------------------------------

We analyzed the role of Spi-C in the regulation of TLR-induced proinflammatory cytokine production by intestinal myeloid cells. Among intestinal CD11b^+^ innate myeloid cells, CX~3~CR1^high^ Mϕs and CX~3~CR1^int/-^ cells from the large intestinal lamina propria were cultured in the presence of LPS and analyzed for the production of IL-6, IL-1α, TNF-α, and IL-10 ([Fig. 4](#fig04){ref-type="fig"}). The Spi-C deficiency in intestinal CX~3~CR1^high^ Mϕs led to increased production of IL-6 and IL-1α, but not of TNF-α and IL-10, while there was no difference in the production of all cytokines by CX~3~CR1^int/-^ cells from control or mutant mice, indicating that Spi-C suppresses a subset of TLR4-inducible genes including *Il6* and *Il1a* in intestinal CX~3~CR1^high^ Mϕs.

![Increased production of IL-6 and IL-1α by intestinal CX~3~CR1^high^ Mϕs of *Lyz2-cre*; *Spic*^*flox/flox*^ mice. (*A*--*D*) LPS-induced production of IL-6 (*A*), IL-1α (*B*), TNF-α (*C*), and IL-10 (*D*) by large intestinal CX~3~CR1^high^ Mϕs and CX~3~CR1^intermediate^ ^(int)/-^ cells. Mean values ± SEM from four independent experiments are shown. n.s., not significant. \**P* \< 0.05.](pnas.1808426115fig04){#fig04}

Dietary Iron Mediates the Induction of Spi-C in Intestinal Innate Myeloid Cells. {#s7}
--------------------------------------------------------------------------------

We next attempted to identify factors driving *Spic* expression in intestinal innate myeloid cells. Heme-mediated degradation of the transcription repressor Bach1 elicits the expression of *Spic* as well as *Hmox1*, *Slc40a1*, and *Blvrb* ([@r19], [@r29]). Previous studies have shown that a reduced intake of dietary iron decreased hemoglobin levels in vivo ([@r30], [@r31]). Thus, we examined the effect of dietary iron on *Spic* expression in large intestinal CX~3~CR1^high^ Mϕs. C57BL/6J mice fed with an AIN93G (control) or iron-reduced (ΔFe) diet were analyzed for the expression of *Spic* in intestinal CX~3~CR1^high^ Mϕs. Mice fed with the ΔFe diet had a lower concentration of blood hemoglobin compared with the control diet ([*SI Appendix*, Fig. S6*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In addition, ΔFe-diet--fed mice exhibited a decreased concentration of iron in the serum, spleen, and colon ([*SI Appendix*, Fig. S6*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In this context, expression of *Spic*, *Hmox1*, *Slc40a1*, and *Blvrb* was reduced in CX~3~CR1^high^ Mϕs isolated from the colon of mice given the ΔFe diet ([*SI Appendix*, Fig. S6*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). Bacterial composition of feces analyzed by 16S rRNA gene sequencing was not altered at the phylum level between mice fed with the AIN93G and ΔFe diet, although a minor Proteobacteria population was slightly increased in the iron deficiency ([*SI Appendix*, Fig. S6*D*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). Thus, the iron deficiency did not alter the bacterial composition at the phylum level in the colon, indicating that the reduced *Spic* expression in the ΔFe-diet--fed mice was not induced by the altered composition of microbiota. To assess the impact of the decline in iron/hemoglobin levels by the ΔFe diet on the TLR-dependent production of proinflammatory cytokines by intestinal CX~3~CR1^high^ Mϕs, we compared the expression of *Il6* and *Tnf* in CX~3~CR1^high^ Mϕs stimulated with or without LPS ([*SI Appendix*, Fig. S6 *E*--*G*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In large intestinal CX~3~CR1^high^ Mϕs from ΔFe-diet--fed mice, the LPS-induced expression of *Il6*, but not of *Tnf*, was markedly increased ([*SI Appendix*, Fig. S6*E*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). Accordingly, IL-6 production in response to LPS by CX~3~CR1^high^ Mϕs was enhanced in mice fed with the ΔFe diet compared with the control diet, whereas TNF-α was normally produced ([*SI Appendix*, Fig. S6*F*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). In contrast, expression of *Il6* was not increased by the ΔFe diet in *Lyz2-cre*; *Spic*^*flox/flox*^ mice ([*SI Appendix*, Fig. S6*G*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). Administration of hemin reduced *Il6* expression in CX~3~CR1^high^ Mϕs of ΔFe-diet--fed *Spic*^*flox/flox*^ mice, but not *Lyz2-cre*; *Spic*^*flox/flox*^ mice ([*SI Appendix*, Fig. S6*G*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). Thus, the reduced *Spic* expression caused by the iron deficiency is associated with the enhanced *Il6* expression in CX~3~CR1^high^ Mϕs.

Spi-C--Mediated Repression of a Subset of LPS-Inducible Genes by Association with IRF5. {#s8}
---------------------------------------------------------------------------------------

Because dietary iron-mediated Spi-C expression is implicated in the down-regulation of *Il6* expression in CX~3~CR1^high^ Mϕs, we examined how Spi-C impacts on the transcriptional initiation of its target genes in Mϕs. Ingenuity Pathway Analysis displayed the upstream regulators of 85 genes up-regulated in *Spic*^*−/−*^ BMMϕs ([*SI Appendix*, Table S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). Among the top five predicted upstream regulators, the IRF family members such as IRF3, IRF7, and IRF5 were included ([Fig. 5*A*](#fig05){ref-type="fig"}). Therefore, we analyzed the association of Spi-C with IRF3, IRF5, and IRF7 by a coimmunoprecipitation assay ([Fig. 5*B*](#fig05){ref-type="fig"}). Among the three molecules, Spi-C interacted with IRF5 and IRF7, but not IRF3. A recent study demonstrated that IRF5-NF-κB p65 complex formation is indispensable for driving the expression of a subset of LPS-inducible genes ([@r32]). Therefore, we examined whether Spi-C altered the association of IRF5 and NF-κB p65 ([Fig. 5*C*](#fig05){ref-type="fig"}). NF-κB p65 bound to IRF5 as previously reported ([@r32]), but not to Spi-C. However, in the presence of Spi-C, formation of the IRF5-NF-κB p65 complex was markedly reduced. In contrast to IRF5, IRF7 did not bind to NF-κB p65 ([Fig. 5*D*](#fig05){ref-type="fig"}). IRF5 recruitment to the NF-κB--binding site in the promoter of its target genes is guided by NF-κB p65 ([@r32]). Therefore, to investigate the effects of the Spi-C--mediated disruption of IRF5-NF-κB p65 complex formation on transcriptional initiation of *Il6* in response to LPS, we analyzed the recruitment of NF-κB p65 and IRF5 to the NF-κB site of the *Il6* promoter in the RAW264.7 cells stably expressing Spi-C-His used in [Figs. 3](#fig03){ref-type="fig"} and [5 *E*--*G*](#fig05){ref-type="fig"}. Chromatin immunoprecipitation assay showed that Spi-C did not bind to the *Il6* promoter even after LPS stimulation ([Fig. 5*E*](#fig05){ref-type="fig"}). In control cells, the LPS-dependent recruitment of IRF5 and NF-κB p65 was observed at the NF-κB site of the *Il6* promoter ([Fig. 5 *F* and *G*](#fig05){ref-type="fig"}). However, neither IRF5 nor NF-κB p65 was recruited to the *Il6* promoter of Spi-C--expressing RAW264.7 cells ([Fig. 5 *F* and *G*](#fig05){ref-type="fig"}). We analyzed the LPS-induced recruitment of IRF5 and NF-κB p65 to the promoters of Spi-C target genes in *Spic*^*−/−*^ BMDMϕ ([Fig. 5 *H* and *I*](#fig05){ref-type="fig"}). BMDMϕ prepared from *Spic*^*flox/flox*^ and *Lyz2-cre*; *Spic*^*flox/flox*^ mice was pretreated with hemin for 18 h and stimulated with LPS. In *Spic*^*−/−*^ BMMϕ, the recruitment of IRF5 to the *Il6* promoter was increased after 1.5 and 5 h of LPS stimulation compared with control cells ([Fig. 5*H*](#fig05){ref-type="fig"}). In addition, elevated IRF5 recruitment to the *Il1a* promoter was observed 5 h after LPS stimulation in *Spic*^*−/−*^ cells ([Fig. 5*H*](#fig05){ref-type="fig"}), and significantly enhanced NF-κB p65 recruitment to the promoters of *Il6* and *Il1a* was found in *Spic*^*−/−*^ BMMϕ relative to that found in control cells ([Fig. 5*I*](#fig05){ref-type="fig"}). Furthermore, the recruitment of IRF5 to the promoters of *Il6* and *Il1a*, but not of *Tnf*, in large intestinal CX~3~CR1^high^ Mϕs was increased in *Lyz2-cre*; *Spic*^*flox/flox*^ mice relative to that in *Spic*^*flox/flox*^ mice during DSS-induced colitis ([*SI Appendix*, Fig. S7](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental)). These findings suggest that Spi-C suppresses the expression of a subset of LPS-inducible genes such as *Il6* and *Il1a* by disrupting formation of the IRF5-NF-κB p65 complex through direct binding to IRF5.

![Spi-C suppresses the expression of a subset of TLR4-dependent genes by interacting with IRF5. (*A*) Enrichment analysis of the upstream transcriptional regulators of genes elevated in *Spic*^*−/−*^ BMDMϕs. (*B*--*D*) Coimmunoprecipitation (IP) assay with anti-His (*B*) and anti--NF-κB p65 (*C* and *D*) antibodies for immunoprecipitation and the indicated antibodies for immunoblotting. (*E*--*G*) ChIP assay for the *Il6* promoter of the NF-κB--binding site was performed with anti-His (*E*), anti-IRF5 (*F*), and anti--NF-κB p65 (*G*) antibodies. All graphs show the mean ± SD. Data are representative of two independent experiments. \*\**P* \< 0.01. n.s., not significant. (*H* and *I*) ChIP assay for the NF-κB site of the *Il6* promoter and *Il1a* promoter was performed with anti-IRF5 (*H*) and anti--NF-κB p65 (*I*) antibodies using control and *Spic*^*−/−*^ BMDMϕs stimulated with LPS following pretreatment with hemin for 18 h. Graphs show the means ± SD. Data are representative of two independent experiments. \**P* \< 0.05, \*\*\*\**P* \< 0.001.](pnas.1808426115fig05){#fig05}

Discussion {#s9}
==========

In this study, we showed that induction of Spi-C by the dietary iron-mediated heme in intestinal CX~3~CR1^high^ Mϕs negatively regulates the transcription of a subset of TLR-inducible genes through IRF5 binding and subsequent disruption of IRF5-NF-κB p65 complex formation, leading to the prevention of intestinal inflammation.

We demonstrated that Spi-C is expressed in CX~3~CR1^high^ Mϕs residing in the large intestine and small intestine. Although a previous study reported that a lack of *Spic* resulted in the absence of splenic RPMϕs ([@r18]), intestinal CX~3~CR1^high^ Mϕs developed normally in *Lyz2-cre*; *Spic*^*flox/flox*^ mice. Thus, it would be important to determine if the reason for this discrepancy is associated with either a differential expression level of *Spic* or distinct progenitors between RPMϕs and intestinal CX~3~CR1^high^ Mϕs in the future.

In the colon of hemin-injected mice, *Spic* expression was increased in CX~3~CR1^high^ Mϕ compared with that in Ly6C^+^ monocytes, which give rise to CX~3~CR1^high^ Mϕs in the intestinal lamina propria, indicating that the induction of Spi-C in CX~3~CR1^high^ Mϕs by hemin might take place locally in the intestine. Intestinal lamina propria CX~3~CR1^high^ Mϕs extend their dendrites into the lumen, where hemoglobin and iron are present even in the steady state. In addition, CX~3~CR1^high^ Mϕs express CD163 ([@r33], [@r34]), which scavenges hemoglobin ([@r35]). Therefore, endocytosis of the luminal hemoglobin-haptoglobin complex through CD163 may induce the expression of *Spic* in intestinal CX~3~CR1^high^ Mϕs. In the current study, we verified that systemic heme supplementation greatly remedied DSS-induced colitis in *Spic*^*flox/flox*^ mice and suppressed *Il6* expression in CX~3~CR1^high^ Mϕs in ΔFe-diet--fed mice. In *Lyz2-cre*; *Spic*^*flox/flox*^ mice, hemin treatment partially prevented severe weight loss during the early phase of DSS-induced colitis and only modestly suppressed expression of *Il6* in ΔFe-diet--fed *Lyz2-cre*; *Spic*^*flox/flox*^ mice. Therefore, systemic heme repletion might abrogate intestinal inflammation in at least two ways: a Spi-C--dependent mechanism and a heme oxynase-1--dependent mechanism as previously reported ([@r23]).

Previous studies have defined that the hemoglobin-mediated modulation of Mϕ phenotypes is implicated in reduction of tissue injury in the brain ([@r10][@r11]--[@r12], [@r36]). Mucosal bleeding is a common symptom of inflammatory bowel diseases such as ulcerative colitis. Therefore, it would be interesting to analyze whether induction of *SPI-C* in human intestinal Mϕs by local hemolysis is implicated in their acquisition of noninflammatory features, thereby associating them with mucosal healing.

The LPS-mediated recruitment of IRF5 to the NF-κB--binding site in the promoters of its target genes was aided by NF-κB p65 ([@r32]). However, whether IRF5 mediates the persistent occupancy of NF-κB p65 in these promoters is unclear. In the present study, we observed a reduced recruitment of NF-κB p65 as well as of IRF5 to the *Il6* promoter in Spi-C stably expressing RAW264.7 cells stimulated with LPS. In addition, the recruitment of NF-κB p65 and IRF5 to the promoters of *Il6* and *Il1a* was enhanced in *Spic*^*−/−*^ BMMϕs. These findings suggest that IRF5 may regulate NF-κB p65 occupancy at the promoters of its target genes. Therefore, it is important to analyze whether the LPS-induced recruitment of NF-κB p65 to the promoters of IRF5 target genes is altered in *Irf5*^*−/−*^ Mϕs. TNF-α is an IRF5-dependent gene as are IL-6 and IL-1α ([@r32]). However, the IRF5 recruitment to the *Tnf* promoter remained normal in *Spic*^*−/−*^ large intestinal CX~3~CR1^high^ Mϕs, suggesting that proper IRF5 occupancy at the *Tnf* promoter is controlled by a Spi-C--independent mechanism. Therefore, it would be important to determine why Spi-C is selectively required for modulation of a subset of IRF5-dependent genes in the future.

Collectively, our results indicate that heme-induced Spi-C in intestinal Mϕs regulates the transcriptional initiation of a subset of TLR4-inducible genes including *Il6* and *Il1a* to attenuate intestinal inflammation. Previous studies demonstrated that treatment with neutralizing IL-6 mAbs improved DSS-induced colitis ([@r37], [@r38]), whereas *Il6*^*−/−*^ mice administrated with DSS showed severe intestinal pathology with reduced epithelial cell proliferation ([@r39]). Therefore, it appears that the IL-6--signaling pathway contributes to the pathogenesis of intestinal inflammation while exerting its homeostatic function by regulating intestinal epithelial integrity. In addition to IL-6, some of the Spi-C target genes such as IL-1α ([@r26][@r27]--[@r28]), TREM-1 ([@r40]), CD38 ([@r41]), and CXCL11 ([@r42]) have been reported to mediate intestinal inflammation. Thus, the development of the method that controls Spi-C expression in human intestinal Mϕs may represent a therapeutic approach for inflammatory bowel diseases.

Materials and Methods {#s10}
=====================

Detailed information on the materials, methods, and associated references can be found in [*SI Appendix*, *SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808426115/-/DCSupplemental).

Mice. {#s11}
-----

C57BL/6J mice were purchased from Japan SLC. *Spic*^*igfp/igfp*^ mice were generated as described previously ([@r19]). All of the mice were maintained under specific pathogen-free conditions. All animal experiments were conducted in accordance with the guidelines of the Animal Care and Use Committee of Osaka University.

ChIP Assay. {#s12}
-----------

BMDMϕs stimulated with 100 ng/mL LPS for the indicated periods following pretreatment with 40 μM hemin for 18 h and intestinal CX~3~CR1^high^ Mϕs were used for ChIP assay according to a previously described protocol ([@r43]). *Il6*- and *Il1a*-specific primers were designed to include the NF-κB--binding site.

Statistical Analysis. {#s13}
---------------------

Differences between the control and experimental groups were evaluated by Student's *t* test. Differences where *P* \< 0.05 were considered statistically significant.
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